{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:55:04Z","timestamp":1786982104256,"version":"build-2736575974"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T00:00:00Z","timestamp":1677196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T00:00:00Z","timestamp":1677196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ir J Med Sci"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s11845-023-03323-8","type":"journal-article","created":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T09:02:57Z","timestamp":1677229377000},"page":"3187-3194","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Circulating PCSK9 relates to aggravated disease activity, Th17\/Treg imbalance, and predicts treatment outcome of conventional synthetic DMARDs in rheumatoid arthritis patients"],"prefix":"10.1007","volume":"192","author":[{"given":"Yanan","family":"Meng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomeng","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijuan","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,24]]},"reference":[{"issue":"13","key":"3323_CR1","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1001\/jama.2018.13103","volume":"320","author":"D Aletaha","year":"2018","unstructured":"Aletaha D, Smolen JS (2018) Diagnosis and management of rheumatoid arthritis: a review. JAMA 320(13):1360\u20131372","journal-title":"JAMA"},{"issue":"11","key":"3323_CR2","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1136\/annrheumdis-2019-215920","volume":"78","author":"S Safiri","year":"2019","unstructured":"Safiri S, Kolahi AA, Hoy D et al (2019) Global, regional and national burden of rheumatoid arthritis 1990\u20132017: a systematic analysis of the Global Burden of Disease study 2017. Ann Rheum Dis 78(11):1463\u20131471","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"3323_CR3","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s00296-020-04731-0","volume":"41","author":"K Almutairi","year":"2021","unstructured":"Almutairi K, Nossent J, Preen D et al (2021) The global prevalence of rheumatoid arthritis: a meta-analysis based on a systematic review. Rheumatol Int 41(5):863\u2013877","journal-title":"Rheumatol Int"},{"issue":"7","key":"3323_CR4","first-page":"593","volume":"60","author":"XP Tian","year":"2021","unstructured":"Tian XP, Li MT, Zeng XF (2021) The challenges and opportunities for the management of rheumatoid arthritis in China: an annual report of 2019. Zhonghua Nei Ke Za Zhi 60(7):593\u2013598","journal-title":"Zhonghua Nei Ke Za Zhi"},{"issue":"4","key":"3323_CR5","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s11926-021-00993-0","volume":"23","author":"VL Kronzer","year":"2021","unstructured":"Kronzer VL, Davis JM 3rd (2021) Etiologies of rheumatoid arthritis: update on mucosal, genetic, and cellular pathogenesis. Curr Rheumatol Rep 23(4):21","journal-title":"Curr Rheumatol Rep"},{"key":"3323_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2019.102400","volume":"110","author":"HU Scherer","year":"2020","unstructured":"Scherer HU, Haupl T, Burmester GR (2020) The etiology of rheumatoid arthritis. J Autoimmun 110:102400","journal-title":"J Autoimmun"},{"key":"3323_CR7","doi-asserted-by":"crossref","unstructured":"Mueller AL, Payandeh Z, Mohammadkhani N et al (2021) Recent advances in understanding the pathogenesis of rheumatoid arthritis: new treatment strategies. Cells 10(11)","DOI":"10.3390\/cells10113017"},{"key":"3323_CR8","doi-asserted-by":"crossref","unstructured":"Radu AF, Bungau SG (2021) Management of rheumatoid arthritis: an overview. Cells 10(11)","DOI":"10.3390\/cells10112857"},{"key":"3323_CR9","doi-asserted-by":"crossref","unstructured":"Lin YJ, Anzaghe M, Schulke S (2020) Update on the pathomechanism, diagnosis, and treatment options for rheumatoid arthritis. Cells 9(4)","DOI":"10.3390\/cells9040880"},{"issue":"10","key":"3323_CR10","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1093\/rheumatology\/kew264","volume":"55","author":"JT Joensuu","year":"2016","unstructured":"Joensuu JT, Aaltonen KJ, Aronen P et al (2016) Cost-effectiveness of biologic compared with conventional synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a Register study. Rheumatology (Oxford) 55(10):1803\u20131811","journal-title":"Rheumatology (Oxford)"},{"key":"3323_CR11","unstructured":"Williams D, Butcher R (2019)\u00a0Triple conventional synthetic disease-modifying anti-rheumatic drugs for the management of rheumatoid arthritis: a review of cost-effectiveness [Internet], Canadian Agency for Drugs and Technologies in Health, Ottawa (ON)"},{"issue":"6","key":"3323_CR12","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","volume":"79","author":"JS Smolen","year":"2020","unstructured":"Smolen JS, Landewe RBM, Bijlsma JWJ et al (2020) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 79(6):685\u2013699","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"3323_CR13","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s00395-015-0463-z","volume":"110","author":"R Schulz","year":"2015","unstructured":"Schulz R, Schluter KD, Laufs U (2015) Molecular and cellular function of the proprotein convertase subtilisin\/kexin type 9 (PCSK9). Basic Res Cardiol 110(2):4","journal-title":"Basic Res Cardiol"},{"key":"3323_CR14","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.taap.2019.03.018","volume":"370","author":"M Brown","year":"2019","unstructured":"Brown M, Ahmed S (2019) Emerging role of proprotein convertase subtilisin\/kexin type-9 (PCSK-9) in inflammation and diseases. Toxicol Appl Pharmacol 370:170\u2013177","journal-title":"Toxicol Appl Pharmacol"},{"key":"3323_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.763516","volume":"9","author":"NQ Wu","year":"2022","unstructured":"Wu NQ, Shi HW, Li JJ (2022) Proprotein convertase subtilisin\/kexin type 9 and inflammation: an updated review. Front Cardiovasc Med 9:763516","journal-title":"Front Cardiovasc Med"},{"issue":"4","key":"3323_CR16","doi-asserted-by":"publisher","first-page":"645","DOI":"10.5114\/ada.2022.118919","volume":"39","author":"A Fratczak","year":"2022","unstructured":"Fratczak A, Polak K, Szczepanek M, Lis-Swiety A (2022) The role of proprotein convertase subtilisin\/kexin type 9 (PCSK9) in the pathophysiology of psoriasis and systemic lupus erythematosus. Postepy Dermatol Alergol 39(4):645\u2013650","journal-title":"Postepy Dermatol Alergol"},{"key":"3323_CR17","doi-asserted-by":"crossref","unstructured":"Krahel JA, Baran A, Kaminski TW, Flisiak I (2020) Proprotein convertase subtilisin\/kexin type 9, angiopoietin-like protein 8, sortilin, and cholesteryl ester transfer protein-friends of foes for psoriatic patients at the risk of developing cardiometabolic syndrome? Int J Mol Sci 21(10)","DOI":"10.3390\/ijms21103682"},{"key":"3323_CR18","doi-asserted-by":"crossref","unstructured":"Liu A, Frostegard J (2018) PCSK9 plays a novel immunological role in oxidized LDL-induced dendritic cell maturation and activation of T cells from human blood and atherosclerotic plaque. J Intern Med","DOI":"10.1016\/j.atherosclerosis.2018.06.113"},{"key":"3323_CR19","doi-asserted-by":"publisher","unstructured":"Sanchez-Perez H, Quevedo-Abeledo JC, Tejera-Segura B et al (2020) Proprotein convertase subtilisin\/kexin type 9 is related to disease activity and damage in patients with systemic erythematosus lupus. Ther Adv Musculoskelet Dis 12. https:\/\/doi.org\/10.1177\/1759720X20975904","DOI":"10.1177\/1759720X20975904"},{"issue":"12","key":"3323_CR20","doi-asserted-by":"publisher","first-page":"3837","DOI":"10.1007\/s10067-022-06315-8","volume":"41","author":"T Wang","year":"2022","unstructured":"Wang T, Rui J, Shan W et al (2022) Imbalance of Th17, Treg, and helper innate lymphoid cell in the peripheral blood of patients with rheumatoid arthritis. Clin Rheumatol 41(12):3837\u20133849","journal-title":"Clin Rheumatol"},{"issue":"1","key":"3323_CR21","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13075-020-02386-7","volume":"23","author":"J Frostegard","year":"2021","unstructured":"Frostegard J, Ahmed S, Hafstrom I et al (2021) Low levels of PCSK9 are associated with remission in patients with rheumatoid arthritis treated with anti-TNF-alpha: potential underlying mechanisms. Arthritis Res Ther 23(1):32","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"3323_CR22","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s13075-020-02240-w","volume":"22","author":"MHY Ma","year":"2020","unstructured":"Ma MHY, Defranoux N, Li W et al (2020) A multi-biomarker disease activity score can predict sustained remission in rheumatoid arthritis. Arthritis Res Ther 22(1):158","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"3323_CR23","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1093\/rheumatology\/keu235","volume":"53","author":"R Fleischmann","year":"2014","unstructured":"Fleischmann R, Koenig AS, Szumski A et al (2014) Short-term efficacy of etanercept plus methotrexate vs combinations of disease-modifying anti-rheumatic drugs with methotrexate in established rheumatoid arthritis. Rheumatology (Oxford) 53(11):1984\u20131993","journal-title":"Rheumatology (Oxford)"},{"key":"3323_CR24","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.phrs.2016.06.016","volume":"111","author":"M Maldonado-Montoro","year":"2016","unstructured":"Maldonado-Montoro M, Canadas-Garre M, Gonzalez-Utrilla A et al (2016) Genetic and clinical biomarkers of tocilizumab response in patients with rheumatoid arthritis. Pharmacol Res 111:264\u2013271","journal-title":"Pharmacol Res"},{"issue":"5","key":"3323_CR25","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1007\/s12325-020-01303-3","volume":"37","author":"J Pope","year":"2020","unstructured":"Pope J, Sawant R, Tundia N et al (2020) Comparative efficacy of JAK inhibitors for moderate-to-severe rheumatoid arthritis: a network meta-analysis. Adv Ther 37(5):2356\u20132372","journal-title":"Adv Ther"},{"issue":"1","key":"3323_CR26","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1080\/1744666X.2022.2017281","volume":"18","author":"J Frostegard","year":"2022","unstructured":"Frostegard J (2022) The role of PCSK9 in inflammation, immunity, and autoimmune diseases. Expert Rev Clin Immunol 18(1):67\u201374","journal-title":"Expert Rev Clin Immunol"},{"issue":"6","key":"3323_CR27","doi-asserted-by":"publisher","DOI":"10.4110\/in.2019.19.e41","volume":"19","author":"YU Kim","year":"2019","unstructured":"Kim YU, Kee P, Danila D, Teng BB (2019) A critical role of PCSK9 in mediating IL-17-producing T cell responses in hyperlipidemia. Immune Netw 19(6):e41","journal-title":"Immune Netw"},{"issue":"10","key":"3323_CR28","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.1093\/rheumatology\/kez660","volume":"59","author":"J Leipe","year":"2020","unstructured":"Leipe J, Pirronello F, Schulze-Koops H, Skapenko A (2020) Altered T cell plasticity favours Th17 cells in early arthritis. Rheumatology (Oxford) 59(10):2754\u20132763","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"3323_CR29","first-page":"655","volume":"56","author":"Q Du","year":"2017","unstructured":"Du Q, Yu XJ, Li HJ et al (2017) The expression and clinical significance of proprotein convertase subtilisin kexin 9 in rheumatoid arthritis. Zhonghua Nei Ke Za Zhi 56(9):655\u2013659","journal-title":"Zhonghua Nei Ke Za Zhi"},{"issue":"6","key":"3323_CR30","doi-asserted-by":"publisher","first-page":"970","DOI":"10.2174\/0929867328666210810150940","volume":"29","author":"S Ministrini","year":"2022","unstructured":"Ministrini S, Carbone F (2022) PCSK9 and inflammation: their role in autoimmune diseases, with a focus on rheumatoid arthritis and systemic lupus erythematosus. Curr Med Chem 29(6):970\u2013979","journal-title":"Curr Med Chem"},{"key":"3323_CR31","doi-asserted-by":"crossref","unstructured":"Rani L, Kumar A, Karhade J et al (2022) IL-3 regulates the differentiation of pathogenic Th17 cells. Eur J Immunol","DOI":"10.1002\/eji.202149674"},{"key":"3323_CR32","doi-asserted-by":"crossref","unstructured":"Wang T, Rui J, Shan W et al (2022) Imbalance of Th17, Treg, and helper innate lymphoid cell in the peripheral blood of patients with rheumatoid arthritis. Clin Rheumatol","DOI":"10.1007\/s10067-022-06315-8"},{"key":"3323_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.689711","volume":"9","author":"VC Romao","year":"2022","unstructured":"Romao VC, Fonseca JE (2022) Disease mechanisms in preclinical rheumatoid arthritis: a narrative review. Front Med (Lausanne) 9:689711","journal-title":"Front Med (Lausanne)"},{"issue":"7","key":"3323_CR34","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1111\/1756-185X.12677","volume":"19","author":"LM Ren","year":"2016","unstructured":"Ren LM, Li R, Chen LN et al (2016) Efficacy and safety of weekly leflunomide for the treatment of early rheumatoid arthritis: a randomized, multi-center study. Int J Rheum Dis 19(7):651\u2013657","journal-title":"Int J Rheum Dis"},{"key":"3323_CR35","doi-asserted-by":"crossref","unstructured":"Li R, Zhao JX, Su Y et al (2016) High remission and low relapse with prolonged intensive DMARD therapy in rheumatoid arthritis (PRINT): a multicenter randomized clinical trial. Medicine (Baltimore) 95(28)","DOI":"10.1097\/MD.0000000000003968"}],"container-title":["Irish Journal of Medical Science (1971 -)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-023-03323-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11845-023-03323-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-023-03323-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T22:17:23Z","timestamp":1701469043000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11845-023-03323-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,24]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["3323"],"URL":"https:\/\/doi.org\/10.1007\/s11845-023-03323-8","relation":{},"ISSN":["0021-1265","1863-4362"],"issn-type":[{"value":"0021-1265","type":"print"},{"value":"1863-4362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,24]]},"assertion":[{"value":"19 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Ethics Committee has approved this research. All patients and healthy individuals provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.\u00a0","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}